PDB Short entry for 2W17 HEADER TRANSFERASE 15-OCT-08 2W17 TITLE CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CYCLIN DEPENDENT KINASE 2, P33 PROTEIN KINASE; COMPND 5 EC: 2.7.11.22; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: ACETYLATION AT N-TERMINAL METHIONINE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: SF21; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS KINASE, MITOSIS, CELL CYCLE, TRANSFERASE, SERINE/THREONINE-PROTEIN KEYWDS 2 KINASE, ATP-BINDING, CELL DIVISION, PHOSPHOPROTEIN, PHOSPHORYLATION, KEYWDS 3 NUCLEOTIDE-BINDING EXPDTA X-RAY DIFFRACTION AUTHOR C.D.JONES,D.M.ANDREWS,A.J.BARKER,K.BLADES,P.DAUNT,S.EAST,C.GEH, AUTHOR 2 M.A.GRAHAM,K.M.JOHNSON,S.A.LODDICK,H.M.MCFARLAND,A.MCGREGOR,L.MOSS, AUTHOR 3 D.A.RUDGE,P.B.SIMPSON,M.L.SWAIN,K.Y.TAM,J.A.TUCKER,M.WALKER, AUTHOR 4 C.BRASSINGTON,H.HAYE,E.MCCALL REVDAT 4 24-APR-19 2W17 1 SOURCE LINK REVDAT 3 13-JUL-11 2W17 1 VERSN REVDAT 2 02-DEC-08 2W17 1 VERSN JRNL REVDAT 1 04-NOV-08 2W17 0 JRNL AUTH C.D.JONES,D.M.ANDREWS,A.J.BARKER,K.BLADES,P.DAUNT,S.EAST, JRNL AUTH 2 C.GEH,M.A.GRAHAM,K.M.JOHNSON,S.A.LODDICK,H.M.MCFARLAND, JRNL AUTH 3 A.MCGREGOR,L.MOSS,D.A.RUDGE,P.B.SIMPSON,M.L.SWAIN,K.Y.TAM, JRNL AUTH 4 J.A.TUCKER,M.WALKER JRNL TITL THE DISCOVERY OF AZD5597, A POTENT IMIDAZOLE PYRIMIDINE JRNL TITL 2 AMIDE CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING. JRNL REF BIOORG.MED.CHEM.LETT. V. 18 6369 2008 JRNL REFN ISSN 0960-894X JRNL PMID 18996007 JRNL DOI 10.1016/J.BMCL.2008.10.102 REMARK 2 REMARK 2 RESOLUTION. 2.15 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.15 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 42.93 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 3 NUMBER OF REFLECTIONS : 15562 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.244 REMARK 3 R VALUE (WORKING SET) : 0.242 REMARK 3 FREE R VALUE : 0.300 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.060 REMARK 3 FREE R VALUE TEST SET COUNT : 779 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 9.39 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 42.93 REMARK 3 REFLECTION IN BIN (WORKING SET) : 212 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2340 REMARK 3 BIN FREE R VALUE SET COUNT : 11 REMARK 3 BIN FREE R VALUE : 0.1230 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2209 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 37 REMARK 3 SOLVENT ATOMS : 150 REMARK 3 REMARK 3 B VALUES. REMARK 3 B VALUE TYPE : LIKELY RESIDUAL REMARK 3 FROM WILSON PLOT (A**2) : 31.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 39.93 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.07300 REMARK 3 B22 (A**2) : 2.66000 REMARK 3 B33 (A**2) : -2.58700 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.361 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.265 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.222 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 18.610 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.941 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.923 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2310 ; 0.012 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 1562 ; 0.004 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3137 ; 1.427 ; 2.000 REMARK 3 BOND ANGLES OTHERS (DEGREES): 3814 ; 0.914 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 275 ; 6.473 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 92 ;39.297 ;23.261 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 392 ;16.179 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 13 ;22.593 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 354 ; 0.077 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2518 ; 0.006 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 453 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 480 ; 0.214 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 1555 ; 0.181 ; 0.200 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1120 ; 0.179 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): 1109 ; 0.088 ; 0.200 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 122 ; 0.190 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 18 ; 0.118 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): 40 ; 0.176 ; 0.200 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 20 ; 0.235 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1403 ; 0.605 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2266 ; 1.089 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 907 ; 1.332 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 871 ; 2.119 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL PLUS MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. DISORDERED REGIONS WERE OMITTED FROM THE MODEL, REMARK 3 DISORDERED SIDE-CHAINS WERE TRUNCATED TO C-BETA. REMARK 4 REMARK 4 2W17 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 15-OCT-08. REMARK 100 THE DEPOSITION ID IS D_1290037770. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-DEC-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : CONFOCAL MIRRORS (VARIMAX) REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU SATURN 92 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : CRYSTALCLEAR REMARK 200 DATA SCALING SOFTWARE : CRYSTALCLEAR REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15575 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.150 REMARK 200 RESOLUTION RANGE LOW (A) : 50.770 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 200 DATA REDUNDANCY : 3.330 REMARK 200 R MERGE (I) : 0.10000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 6.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.15 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.23 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.9 REMARK 200 DATA REDUNDANCY IN SHELL : 3.30 REMARK 200 R MERGE FOR SHELL (I) : 0.39000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: INTERNAL CDK2 STRUCTURE MODEL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.06 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 8% PEG 3350, 0.1M HEPES PH 7.5, 0.05M REMARK 280 AMMONIUM ACETATE REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 26.77100 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 35.88550 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 35.91200 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 35.88550 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 26.77100 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 35.91200 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 13 REMARK 465 THR A 39 REMARK 465 GLU A 40 REMARK 465 THR A 41 REMARK 465 GLU A 42 REMARK 465 GLY A 43 REMARK 465 ASN A 74 REMARK 465 ARG A 150 REMARK 465 ALA A 151 REMARK 465 PHE A 152 REMARK 465 GLY A 153 REMARK 465 VAL A 154 REMARK 465 PRO A 155 REMARK 465 VAL A 156 REMARK 465 ARG A 157 REMARK 465 THR A 158 REMARK 465 TYR A 159 REMARK 465 THR A 160 REMARK 465 HIS A 161 REMARK 465 GLU A 162 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 MET A 1 CG SD CE REMARK 470 GLU A 12 CG CD OE1 OE2 REMARK 470 THR A 14 OG1 CG2 REMARK 470 TYR A 15 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 LYS A 34 CE NZ REMARK 470 ARG A 36 CG CD NE CZ NH1 NH2 REMARK 470 ASP A 38 CG OD1 OD2 REMARK 470 GLU A 57 CD OE1 OE2 REMARK 470 LYS A 75 CG CD CE NZ REMARK 470 VAL A 164 CG1 CG2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 2012 O HOH A 2123 2564 2.05 REMARK 500 OE2 GLU A 73 ND2 ASN A 272 2464 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 36 77.33 -41.69 REMARK 500 LEU A 37 168.92 -30.07 REMARK 500 THR A 72 106.30 -165.69 REMARK 500 GLU A 81 131.33 -36.97 REMARK 500 ALA A 95 1.50 -68.12 REMARK 500 ARG A 126 -13.15 82.47 REMARK 500 ASP A 127 51.82 -151.21 REMARK 500 TYR A 179 63.00 -109.36 REMARK 500 PRO A 254 48.63 -108.42 REMARK 500 ASP A 288 33.85 -98.84 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2015 DISTANCE = 7.71 ANGSTROMS REMARK 525 HOH A2016 DISTANCE = 5.94 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACE A 0 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A1299 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE I19 A1300 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2VTH RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2VTA RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 2VTT RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2VTQ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 2W05 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5B REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9- REMARK 900 TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2VTM RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 2VTN RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2W06 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5C REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC REMARK 900 AMINOPYRIMIDINE REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 2VTI RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 2VTS RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2G9X RELATED DB: PDB REMARK 900 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH REMARK 900 THE INHIBITOR NU6271 REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 2VTP RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 2VU3 RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2VTL RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2VTJ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 2V22 RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 2VV9 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 2VTO RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, REMARK 900 CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 2VTR RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR DBREF 2W17 A 0 0 PDB 2W17 2W17 0 0 DBREF 2W17 A 1 298 UNP P24941 CDK2_HUMAN 1 298 SEQRES 1 A 299 ACE MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU SEQRES 2 A 299 GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU SEQRES 3 A 299 THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP SEQRES 4 A 299 THR GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU SEQRES 5 A 299 ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL SEQRES 6 A 299 LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR SEQRES 7 A 299 LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE SEQRES 8 A 299 MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU SEQRES 9 A 299 ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA SEQRES 10 A 299 PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS SEQRES 11 A 299 PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS SEQRES 12 A 299 LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO SEQRES 13 A 299 VAL ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR SEQRES 14 A 299 ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER SEQRES 15 A 299 THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA SEQRES 16 A 299 GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER SEQRES 17 A 299 GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY SEQRES 18 A 299 THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET SEQRES 19 A 299 PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN SEQRES 20 A 299 ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY SEQRES 21 A 299 ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN SEQRES 22 A 299 LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE SEQRES 23 A 299 PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU HET ACE A 0 3 HET ACT A1299 4 HET I19 A1300 33 HETNAM ACE ACETYL GROUP HETNAM ACT ACETATE ION HETNAM I19 N-(4-{[(3S)-3-(DIMETHYLAMINO)PYRROLIDIN-1- HETNAM 2 I19 YL]CARBONYL}PHENYL)-5-FLUORO-4-[2-METHYL-1-(1- HETNAM 3 I19 METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-AMINE FORMUL 1 ACE C2 H4 O FORMUL 2 ACT C2 H3 O2 1- FORMUL 3 I19 C24 H30 F N7 O FORMUL 4 HOH *150(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 ALA A 170 LEU A 175 1 6 HELIX 5 5 THR A 182 ARG A 199 1 18 HELIX 6 6 SER A 207 GLY A 220 1 14 HELIX 7 7 GLY A 229 MET A 233 5 5 HELIX 8 8 ASP A 247 VAL A 252 1 6 HELIX 9 9 ASP A 256 LEU A 267 1 12 HELIX 10 10 SER A 276 ALA A 282 1 7 HELIX 11 11 HIS A 283 GLN A 287 5 5 SHEET 1 AA 5 PHE A 4 GLY A 11 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 LYS A 34 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LEU A 76 GLU A 81 -1 O LEU A 78 N LYS A 33 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 LINK C ACE A 0 N MET A 1 1555 1555 1.35 CISPEP 1 THR A 72 GLU A 73 0 4.83 CISPEP 2 PRO A 253 PRO A 254 0 13.92 SITE 1 AC1 5 MET A 1 GLU A 2 ASN A 3 ILE A 70 SITE 2 AC1 5 TYR A 179 SITE 1 AC2 2 SER A 106 THR A 290 SITE 1 AC3 14 ILE A 10 VAL A 18 ALA A 31 LYS A 33 SITE 2 AC3 14 VAL A 64 PHE A 80 GLU A 81 LEU A 83 SITE 3 AC3 14 HIS A 84 GLN A 85 ASP A 86 GLN A 131 SITE 4 AC3 14 LEU A 134 ASP A 145 CRYST1 53.542 71.824 71.771 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.018677 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013923 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013933 0.00000 HETATM 1 C ACE A 0 -14.217 33.995 -3.047 1.00 65.77 C HETATM 2 O ACE A 0 -13.449 34.393 -3.916 1.00 65.76 O HETATM 3 CH3 ACE A 0 -15.385 34.831 -2.613 1.00 65.67 C